



Geron to Present at Upcoming Investor Conferences in April

4/12/2023

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to participate in fireside chats at following investor conferences:

- 22nd Annual Needham Virtual Healthcare Conference
Thursday, April 20 at 10:15 a.m. ET
- Stifel 2023 Virtual Targeted Oncology Days
Tuesday, April 25 at 2:00 p.m. ET

A webcast of each fireside chat and corporate presentation will be available through the Investor Relations section of Geron's website under **Events**. Following each scheduled conference event, the related webcast will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Its investigational first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize winning science in a treatment that may alter the underlying course of these diseases. To learn more, visit <http://www.geron.com>/or follow us on **LinkedIn**.

Aron Feingold
Investor and Media Relations
investor@geron.com
media@geron.com

Source: Geron Corporation